Athersys Company Profile

21:52 EST 3rd March 2015 | BioPortfolio

Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.
As represented by its name, (Athersys - derived from advanced therapeutic systems), the Company is committed to developing novel therapeutic products that deliver substantial improvements over existing therapies through the application and utilization of its advanced, proprietary technology platforms.

Through internal development and acquisition of key technologies, Athersys has established a unique blend of competencies in areas such as molecular biology, cell biology, genomics, protein biochemistry, medicinal chemistry, and pharmacology. The Company has fully integrated pre-clinical drug discovery and development capabilities, and is focused on advancing a portfolio of therapeutic development programs into the clinic.

Location

3201 Carnegie Avenue
Cleveland
Ohio
44115-2634
United States of America

Contact

Phone: 216-431-9900
Fax: 216-361-9495
Email: jobs@athersys.com., ir@athersys.com


News Articles [21 Associated News Articles listed on BioPortfolio]

Athersys, Inc.: Athersys und Chugai schließen Lizenzvereinbarung und Zusammenarbeit zum Entwickeln der MultiStem(R)-Stammzellentherapie für ischämische Schlaganfälle in Japan ab

Partnerschaft im Bereich der regenerativen Medizin mit dem Schwerpunkt auf der Entwicklung einer neuen Stammzellentherapie CLEVELAND und TOKIO, 3. März 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nas...

Athersys and Chugai announce pharma licensing deal for ischemic stroke

Athersys and Chugai Pharmaceutical have announced a partnership and pharma licensing agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan. Ischemic s...

Athersys (ATHX) - Poised for pivotal stroke data

Edison Investment Research - Pharmaceutical & Healthcare - Athersys : Enrolment in the potentially pivotal Phase II study assessing MultiStem in ischaemic stroke patients is now complete. With a 90-da...

Chugai Signals Cell Therapy Interest Via Athersys Deal

The U.S. venture Athersys has entered into a cell therapy alliance with Chugai that will enable it to take advantage of the newly supportive regulatory environment in Japan for regenerative medicines ...

Athersys und Chugai schliessen Lizenzvereinbarung und Zusammenarbeit zum Entwickeln der MultiStem(R)-Stammzellentherapie fur ischamische Schlaganfalle in Japan ab

Athersys und Chugai schliessen Lizenzvereinbarung und Zusammenarbeit zum Entwickeln der MultiStem(R)-Stammzellentherapie fur ischamische Schlaganfalle in Japan ab DGAP-News: Athersys, Inc. Athersy...

Chugai buys Japan rights to Athersys' MultiStem for stroke

Athersys Inc. (NASDAQ:ATHX) jumped $0.36 (14%) to $2.95 on Monday after granting Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) Japanese rights to develop and commercialize its MultiStem cell therapy for...

Grant Awarded for MultiStem(R) Therapy Clinical Trial in United Kingdom for ARDS

SOURCE January 22, 2015 Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition Innovate UK Grant Awarded for Mult...

Athersys Reports Third Quarter 2014 Results

CLEVELAND, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the three months ended September 30, 2014. Highlights of the third quarter of 2014 ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Athersys

Athersys is a biopharmaceutical company engaged in the development and commercialization of therapeutic products that treat significant and life-threatening diseases.As represented by its name, (Ather...

Athersys Incorporated

Athersys is a biotechnology company engaged in the research and development of products for the treatment and diagnosis of genetic and immunologic disorders. The company has a core expertise in the f...

Athersys, Inc.

Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company ...

More Information about "Athersys" on BioPortfolio

We have published hundreds of Athersys news stories on BioPortfolio along with dozens of Athersys Clinical Trials and PubMed Articles about Athersys for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Athersys Companies in our database. You can also find out about relevant Athersys Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record